Low‐grade serous carcinomas of the ovary contain very few point mutations
暂无分享,去创建一个
K. Kinzler | B. Vogelstein | V. Velculescu | Siân Jones | N. Papadopoulos | I. Shih | Tian-Li Wang | R. Kurman | K. Nakayama
[1] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[2] I. Shih,et al. Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma , 2011, The American journal of surgical pathology.
[3] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[4] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[5] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[6] S. Mok,et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. , 2010, The American journal of pathology.
[7] D. Heimbrook,et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.
[8] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[9] Carl Virtanen,et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. , 2010, Gynecologic oncology.
[10] P. Rosenberg,et al. Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[11] V. Velculescu,et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.
[12] I. Shih,et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. , 2009, Cancer research.
[13] M. Fukumoto,et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer , 2008, British Journal of Cancer.
[14] S. Plaxe. Epidemiology of low-grade serous ovarian cancer. , 2008, American journal of obstetrics and gynecology.
[15] Martin A. Nowak,et al. Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.
[16] I. Shih,et al. The Development of High-grade Serous Carcinoma From Atypical Proliferative (Borderline) Serous Tumors and Low-grade Micropapillary Serous Carcinoma: A Morphologic and Molecular Genetic Analysis , 2007, The American journal of surgical pathology.
[17] D. Bodurka,et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. , 2007, Gynecologic oncology.
[18] U. Löhrs,et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.
[19] A. Sood,et al. Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary , 2006, Obstetrics and gynecology.
[20] L. Cope,et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms , 2006, Cancer biology & therapy.
[21] I. Shih,et al. Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges , 2005, Clinical Cancer Research.
[22] Tian-Li Wang,et al. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. , 2005, Cancer research.
[23] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[24] Chung-Liang Ho,et al. Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas , 2004, Clinical Cancer Research.
[25] Chung-Liang Ho,et al. Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.
[26] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[27] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[28] A. Flanagan,et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.
[29] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[30] M. Sherman,et al. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. , 1996, The American journal of surgical pathology.
[31] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[32] Illinois.,et al. Cancer Genetics , 1976, British Journal of Cancer.
[33] A. Jemal,et al. Global Cancer Statistics , 2011 .
[34] M. Gordon,et al. RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models , 2010 .
[35] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.